Relative to x1/2pal-con-treated tumours, treatment with the CXCR1/2-targeting x1/2pal-i3 pepducin attenuated tumour growth (34.7 ± 0.91 days; P = 0.0003), producing a comparable growth delay to radiation (3 Gy; 35.7 ± 2.008 days). This evidence concerns the gene CXCR1 and neoplasm.